fenoldopam has been researched along with Kidney Diseases in 36 studies
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vasoactive compounds are known to affect intrarenal hemodynamics and gene transcription, but specific effects of fenoldopam in the setting of acute renal ischemia are not known." | 3.73 | Fenoldopam improves corticomedullary oxygen delivery and attenuates angiogenesis gene expression in acute ischemic renal injury. ( Aravindan, N; Riedel, B; Samuels, J; Shaw, A, 2006) |
| "Fenoldopam was infused at a low dose of 0." | 2.73 | Fenoldopam in newborn patients undergoing cardiopulmonary bypass: controlled clinical trial. ( Di Chiara, L; Giorni, C; Morelli, S; Picardo, S; Ricci, Z; Ronco, C; Stazi, GV; Vitale, V, 2008) |
| " Median contrast dosage was 120 mL (range 50-200)." | 2.73 | Targeted renal therapy and contrast-induced nephropathy during endovascular abdominal aortic aneurysm repair: results of a feasibility pilot trial. ( Allie, DE; Hebert, CJ; Keller, VA; Lirtzman, MD; Mitran, EV; Patlola, R; Veerina, KK; Walker, CM; Wyatt, CH, 2007) |
| " Of seven prospective studies using various dosing regimens of N-acetylcysteine, four revealed beneficial results." | 2.42 | Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. ( Brokering, KL; Theobald, JC; Walker, PD, 2003) |
| "Fenoldopam is an interesting orphan drug that is a variant of dopamine." | 1.31 | Preventing contrast-induced nephropathy with fenoldopam. ( Bjarnason, H; Chamsuddin, A; Hunter, DW; Kowalik, K, 2001) |
| "The fenoldopam infusion was started 20 min before amphotericin B and was continued for the duration of the experiment." | 1.28 | Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. ( Brooks, DP; Koster, PF; Nichols, AJ; Ruffolo, RR, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 31 (86.11) | 29.6817 |
| 2010's | 2 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ricci, Z | 2 |
| Stazi, GV | 1 |
| Di Chiara, L | 1 |
| Morelli, S | 1 |
| Vitale, V | 1 |
| Giorni, C | 1 |
| Ronco, C | 2 |
| Picardo, S | 1 |
| Caixeta, A | 1 |
| Mehran, R | 3 |
| Rundback, JH | 1 |
| Nahl, D | 1 |
| Yoo, V | 1 |
| Chamsuddin, AA | 1 |
| Kowalik, KJ | 1 |
| Bjarnason, H | 2 |
| Dietz, CA | 1 |
| Rosenberg, MS | 1 |
| Gomes, MD | 1 |
| McDermott, CM | 1 |
| Hunter, DW | 2 |
| Allaqaband, S | 1 |
| Tumuluri, R | 1 |
| Malik, AM | 1 |
| Gupta, A | 1 |
| Volkert, P | 1 |
| Shalev, Y | 1 |
| Bajwa, TK | 1 |
| Brinker, JA | 1 |
| Lepor, NE | 3 |
| Mathur, VS | 1 |
| Caimmi, PP | 1 |
| Pagani, L | 1 |
| Micalizzi, E | 1 |
| Fiume, C | 1 |
| Guani, S | 1 |
| Bernardi, M | 1 |
| Parodi, F | 1 |
| Cordero, G | 1 |
| Fregonara, M | 1 |
| Kapetanakis, E | 1 |
| Panella, M | 1 |
| Degasperis, C | 1 |
| Stone, GW | 1 |
| McCullough, PA | 1 |
| Tumlin, JA | 1 |
| Madyoon, H | 2 |
| Murray, P | 1 |
| Wang, A | 1 |
| Chu, AA | 1 |
| Schaer, GL | 1 |
| Stevens, M | 1 |
| Wilensky, RL | 1 |
| O'Neill, WW | 1 |
| Walker, PD | 1 |
| Brokering, KL | 1 |
| Theobald, JC | 1 |
| Del Vecchio, L | 1 |
| Morcos, SK | 1 |
| De Shong, D | 1 |
| Mathis, AS | 1 |
| Briguori, C | 1 |
| Colombo, A | 1 |
| Airoldi, F | 1 |
| Violante, A | 1 |
| Castelli, A | 1 |
| Balestrieri, P | 1 |
| Paolo Elia, P | 1 |
| Golia, B | 1 |
| Lepore, S | 1 |
| Riviezzo, G | 1 |
| Scarpato, P | 1 |
| Librera, M | 1 |
| Focaccio, A | 1 |
| Ricciardelli, B | 1 |
| Biancofiore, G | 1 |
| Della Rocca, G | 1 |
| Bindi, L | 1 |
| Romanelli, A | 1 |
| Esposito, M | 1 |
| Meacci, L | 1 |
| Urbani, L | 1 |
| Filipponi, F | 1 |
| Mosca, F | 1 |
| Rocca, GD | 1 |
| Pompei, L | 1 |
| Costa, MG | 1 |
| Coccia, C | 1 |
| Scudeller, L | 1 |
| Marco, PD | 1 |
| Monaco, S | 1 |
| Pietropaoli, P | 1 |
| Ng, TM | 1 |
| Shurmur, SW | 1 |
| Silver, M | 1 |
| Nissen, LR | 1 |
| O'Leary, EL | 1 |
| Rigmaiden, RS | 1 |
| Cieciorka, M | 1 |
| Porter, LL | 1 |
| Ineck, BA | 1 |
| Kline, ME | 1 |
| Puumala, SE | 1 |
| van den Berk, G | 1 |
| Tonino, S | 1 |
| de Fijter, C | 1 |
| Smit, W | 1 |
| Schultz, MJ | 1 |
| Pannu, N | 1 |
| Tonelli, M | 1 |
| Aravindan, N | 1 |
| Samuels, J | 1 |
| Riedel, B | 1 |
| Shaw, A | 1 |
| Allie, DE | 1 |
| Lirtzman, MD | 1 |
| Wyatt, CH | 1 |
| Keller, VA | 1 |
| Mitran, EV | 1 |
| Hebert, CJ | 1 |
| Patlola, R | 1 |
| Veerina, KK | 1 |
| Walker, CM | 1 |
| Pucelikova, T | 1 |
| Dangas, G | 1 |
| Cogliati, AA | 1 |
| Vellutini, R | 1 |
| Nardini, A | 1 |
| Urovi, S | 1 |
| Hamdan, M | 1 |
| Landoni, G | 1 |
| Guelfi, P | 1 |
| Moffett, BS | 1 |
| Mott, AR | 1 |
| Nelson, DP | 1 |
| Goldstein, SL | 1 |
| Jefferies, JL | 1 |
| Ackerman, DM | 1 |
| Blumberg, AL | 1 |
| McCafferty, JP | 1 |
| Sherman, SS | 1 |
| Weinstock, J | 1 |
| Kaiser, C | 1 |
| Berkowitz, B | 1 |
| Murphy, MB | 1 |
| Murray, C | 1 |
| Shorten, GD | 1 |
| Kini, AS | 2 |
| Mitre, CA | 2 |
| Kim, M | 2 |
| Kamran, M | 2 |
| Reich, D | 1 |
| Sharma, SK | 2 |
| Suleman, J | 1 |
| Duffy, ME | 1 |
| Marmur, JD | 1 |
| Chamsuddin, A | 1 |
| Kowalik, K | 1 |
| Croushore, L | 1 |
| Nichols, AJ | 1 |
| Koster, PF | 1 |
| Brooks, DP | 2 |
| Ruffolo, RR | 2 |
| Drutz, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intraoperative Fenoldopam Infusion in Children Requiring Cardiopulmonary Bypass During Cardiac Surgery[NCT00982527] | Phase 3 | 80 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury[NCT01098032] | Phase 3 | 294 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging[NCT02114697] | Phase 4 | 9 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to The study was stopped when the original principal investigator moved to a new institution.) | ||
| Pre-existing Microalbuminuria Predicting Contrast-induced Acute Kidney Injury (CIAKI) Following Coronary Angiography (CAG)[NCT02808845] | 800 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| Early Detection of Contrast Induced Nephropathy After Coronary Angiography : Predictive Value of Osteopontin[NCT05547581] | 155 participants (Anticipated) | Observational | 2022-12-07 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure will be the rate of development of CI-AKI in the 2 study arms (number of participants). CI-AKI is defined as an increase in the serum creatinine concentration >=0.3 mg/dL from the baseline value at 48 hours after administration of the contrast media or the need for dialysis. (NCT01098032)
Timeframe: at 48 hours following contrast exposure
| Intervention | participants (Number) |
|---|---|
| Systemic Alone Therapy Group | 146 |
| RenalGuard System Group | 146 |
Plaque volume of carotid arteries were measured by MRI as a surrogate for progression of cardiovascular disease. Plaque volume varies with observed ranges from other studies ranging from 23.9 to 604.1mm^3. Plaque volume tends to increase with age. Increased plaque volume has an increased risk of vascular events. (NCT02114697)
Timeframe: Baseline, 18 months, 36 months
| Intervention | Cubic millimeter (mm^3) (Mean) |
|---|---|
| Baseline | |
| Lifestyle Modification | 125.18 |
Plaque volume of carotid arteries were measured by MRI as a surrogate for progression of cardiovascular disease. Plaque volume varies with observed ranges from other studies ranging from 23.9 to 604.1mm^3. Plaque volume tends to increase with age. Increased plaque volume has an increased risk of vascular events. (NCT02114697)
Timeframe: Baseline, 18 months, 36 months
| Intervention | Cubic millimeter (mm^3) (Mean) | |
|---|---|---|
| Baseline | Month 18 | |
| Statin Therapy | 108.88 | 114.70 |
12 reviews available for fenoldopam and Kidney Diseases
| Article | Year |
|---|---|
Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Disease; Angioplasty, Balloon, Coronary; Contrast Media; Dopamine; Drug Admini | 2010 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Antioxidants; Contrast Media; Evidence-Based Medicine; Fenoldopam; Fluid Therapy; Hu | 2011 |
A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.
Topics: Acetylcysteine; Animals; Contrast Media; Diabetes Complications; Dogs; Dopamine Agonists; Evaluation | 2003 |
The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients.
Topics: Critical Illness; Dopamine Agonists; Fenoldopam; Humans; Hypertension; Kidney Diseases; Liver Transp | 2003 |
A review of pharmacologic interventions to prevent contrast-induced nephropathy.
Topics: Acetylcysteine; Adenosine; Calcium Channel Blockers; Contrast Media; Creatinine; Fenoldopam; Furosem | 2003 |
Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.
Topics: Acetylcysteine; Contrast Media; Dopamine Agonists; Fenoldopam; Free Radical Scavengers; Humans; Isch | 2003 |
Prevention of contrast media nephrotoxicity--the story so far.
Topics: Acetylcysteine; Alprostadil; Atrial Natriuretic Factor; Contrast Media; Dopamine; Dopamine Agonists; | 2004 |
Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients.
Topics: Acetylcysteine; Contrast Media; Critical Care; Fenoldopam; Free Radical Scavengers; Hemofiltration; | 2005 |
Strategies to reduce the risk of contrast nephropathy: an evidence-based approach.
Topics: Acetylcysteine; Ascorbic Acid; Contrast Media; Evidence-Based Medicine; Fenoldopam; Humans; Kidney D | 2006 |
Contrast-induced nephropathy remains a serious complication of PCI.
Topics: Acetylcysteine; Angioplasty, Balloon, Coronary; Contrast Media; Disease Progression; Fenoldopam; Hum | 2007 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Dopamine Agonists; Drug Synergism; Fenoldopam; Hum | 2001 |
11 trials available for fenoldopam and Kidney Diseases
| Article | Year |
|---|---|
Fenoldopam in newborn patients undergoing cardiopulmonary bypass: controlled clinical trial.
Topics: Cardiac Surgical Procedures; Cardiopulmonary Bypass; Creatinine; Critical Care; Dopamine Agonists; F | 2008 |
Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzy | 2002 |
Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiopulmonary Bypass; Creatinine; Diuretics; Dopamine Agonist | 2003 |
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Topics: Adult; Aged; Angiography; Angioplasty, Balloon, Coronary; Contrast Media; Creatinine; Dopamine Agoni | 2003 |
N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
Topics: Acetylcysteine; Administration, Oral; Aged; Contrast Media; Coronary Angiography; Coronary Artery Di | 2004 |
Use of fenoldopam to control renal dysfunction early after liver transplantation.
Topics: Adult; Antibodies, Monoclonal; Basiliximab; Creatinine; Cyclosporine; Dopamine; Dopamine Agonists; D | 2004 |
Fenoldopam mesylate and renal function in patients undergoing liver transplantation: a randomized, controlled pilot trial.
Topics: Acute Kidney Injury; Adult; Aged; Blood Urea Nitrogen; Blood Volume; Cyclosporine; Diuretics; Dopami | 2004 |
Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
Topics: Acetylcysteine; Adult; Aged; Cardiac Catheterization; Contrast Media; Female; Fenoldopam; Humans; Ki | 2006 |
'Renal-dose' fenoldopam for early-stage renal dysfunction in critically ill patients.
Topics: Adult; Critical Illness; Dopamine Agonists; Fenoldopam; Humans; Kidney Diseases; Prospective Studies | 2006 |
Targeted renal therapy and contrast-induced nephropathy during endovascular abdominal aortic aneurysm repair: results of a feasibility pilot trial.
Topics: Aged; Aortic Aneurysm, Abdominal; Blood Vessel Prosthesis Implantation; Contrast Media; Dopamine Ago | 2007 |
Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study.
Topics: Aged; Cardiopulmonary Bypass; Creatinine; Female; Fenoldopam; Fluid Therapy; Humans; Infusions, Intr | 2007 |
13 other studies available for fenoldopam and Kidney Diseases
| Article | Year |
|---|---|
Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Dopamine Agonists; Female; Fenoldopam; Humans; Kidne | 2002 |
The third strike.
Topics: Acetylcysteine; Antihypertensive Agents; Cardiovascular Diseases; Contrast Media; Fenoldopam; Free R | 2002 |
American society of nephrology-36th annual meeting and renal week 2003.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Calcium; Diabetic Nephr | 2004 |
Lessons in formulary management: the case of fenoldopam for radiographic contrast material-induced nephropathy.
Topics: Contrast Media; Fenoldopam; Formularies as Topic; Humans; Kidney; Kidney Diseases; Randomized Contro | 2004 |
Fenoldopam improves corticomedullary oxygen delivery and attenuates angiogenesis gene expression in acute ischemic renal injury.
Topics: Acute Disease; Analysis of Variance; Angiogenesis Inducing Agents; Animals; Fenoldopam; Gene Express | 2006 |
Renal effects of fenoldopam in critically ill pediatric patients: A retrospective review.
Topics: Adolescent; Adult; Child; Child, Preschool; Creatinine; Critical Illness; Diuresis; Dopamine Agonist | 2008 |
Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526.
Topics: Animals; Benzazepines; Blood Pressure; Dogs; Fenoldopam; Hypertension; Isomerism; Kidney; Kidney Dis | 1983 |
A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Contrast Media; Creatinine; Dopami | 2002 |
Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.
Topics: Aged; Atherectomy, Coronary; Cardiac Catheterization; Contrast Media; Diabetic Nephropathies; Dopami | 2002 |
Preventing contrast-induced nephropathy with fenoldopam.
Topics: Animals; Blood Pressure; Contrast Media; Dopamine Agonists; Dose-Response Relationship, Drug; Fenold | 2001 |
Use of fenoldopam for prevention of radiocontrast nephropathy in the cardiac catheterization laboratory: a case series.
Topics: Aged; Aged, 80 and over; Cardiac Catheterization; Contrast Media; Female; Fenoldopam; Humans; Kidney | 2001 |
Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphotericin B; Animals; Creatinine; Dog | 1992 |
Prevention and complete reversal of cyclosporine A-induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Body Weight; Cyclosporins; Feno | 1990 |